Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study.

Delphine Casabonne, Yolanda Benavente, Julia Seifert, Laura Costas, María Armesto, María Arestin, Caroline Besson, Fatemeh S. Hosnijeh, Eric J. Duell, Elisabete Weiderpass, Giovanna Masala, Rudolf Kaaks, Federico Canzian, María-Dolores Chirlaque, Vittorio Perduca, Francesca R. Mancini, Valeria Pala, Antonia Trichopoulou, Anna Karakatsani, Carlo La VecchiaMaria-Jose Sánchez, Rosario Tumino, Marc J. Gunter, Pilar Amiano, Salvatore Panico, Carlotta Sacerdote, Julie A. Schmidt, Heiner Boeing, Matthias B. Schulze, Aurelio Barricarte, Elio Riboli, Anja Olsen, Anne Tjønneland, Roel Vermeulen, Alexandra Nieters, Charles H. Lawrie, Silvia de Sanjosé

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study.'. Together they form a unique fingerprint.

Medicine & Life Sciences